oprozomib and Neoplasm-Metastasis

The oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase Ib/II study results investigating single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia.. The primary objectives were to determine the MTD, safety, and tolerability of oprozomib (phase Ib) as well as overall response rate (ORR; phase II). Oprozomib was administered once daily on days 1, 2, 8, and 9 (2/7 schedule) or days 1 to 5 (5/14 schedule) of a 14-day cycle.. This study demonstrated promising efficacy of single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia.

Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Staging; Oligopeptides; Proteasome Inhibitors; Severity of Illness Index; Treatment Outcome; Waldenstrom Macroglobulinemia